Acadia Pharmaceuticals | ACAD - Interest Expense On Debt


Acadia Pharmaceuticals reported $0 in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 27.55M 1.63M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Cara Therapeutics 23.53M 113.18M Sep/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Cytokinetics USD 38.48M 3.65M Sep/2026
Eisai JPY 2.18B 220M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Incyte USD 605K 23K Sep/2026
J&J USD 43M 25M Mar/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Prothena USD 283.52M 19.06M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026